Users, markets and psychoactive substances: recent developments (2018-2019)
Tendances n° 136, OFDT, 8 p.
Since 1999, the Emerging Trends and New Drugs (TREND) unit of the French Monitoring Centre for Drugs and Drug Addiction (OFDT) has been monitoring emerging trends and phenomena in the field of drugs. It focuses on populations that mostly consume psychoactive substances and is based on qualitative data collected by the network of TREND sites located in eight metropolitan areas.
The developments observed in 2018 confirm those highlighted in previous years. With regard to users, the living conditions of the most marginalised are deteriorating, as observed cyclically, especially in the case of young people and/or migrants. Some networks are rationalising their activities by adopting the organisational methods of traditional companies: marketing strategies, reducing stock, making the workforce more flexible, etc. At the same time, the diversity of available products is steadily rising and consumption of substances previously confined to certain environments (ketamine, GHB-GBL, nitrous oxide) is expanding.
Authors : Clément Gérome, Agnès Cadet-Taïrou, Michel Gandilhon, Maitena Milhet, Victor Detrez, Magali Martinez
Download the PDF file (538 Ko)
Drugs in Europe
How is the COVID-19 pandemic affecting drug use, supply and services?
Drug use and harms
What are the health costs of drug use in Europe today?
What do the latest data tell us about drug production and trafficking trends?
These and other questions are explored in the 2021 European Drug Report, our annual overview of the drug situation in Europe.
The annual Statistical Bulletin contains the most recent available data on the drug situation in Europe provided by the Member States. These datasets underpin the analysis presented in the European Drug Report. All data may be viewed interactively on screen and downloaded in Excel format..
The European Union and the drug phenomenon
The European Union & the drug phenomenon : Frequently asked questions, joint publication between the EMCDDA and the European Commission, october 2010, 12 p.